Experimental studies suggest that pioglitazone may upregulate ACE2 in insulin-sensitive tissues and, although this effect in the lung is still uncertain, this supposed increase in ACE2 expression has raised some concerns about the use of this drug in patients with diabetes and COVID-19 [104, 115–117]. This evidence concerns the gene ACE2 and COVID-19.